Literature DB >> 21112326

MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.

Jun Hao1, Shuyu Zhang, Yingqi Zhou, Xiangui Hu, Chenghao Shao.   

Abstract

Both deregulation of tumor-suppressor genes and misexpression of microRNAs (miRNAs) have been implicated in the development of pancreatic cancer, but their relationship during this process remains less clear. Here, we report that the expression of miR-483-3p is strongly enhanced in pancreatic cancer tissues compared to side normal tissues using a miRNA-array differential analysis. Furthermore, DPC4/Smad4 is identified as a target of miR-483-3p and their expression levels are inversely correlated in human clinical specimens. Ectopic expression of miR-483-3p significantly represses DPC4/Smad4 protein levels in pancreatic cancer cell lines, and simultaneously promotes cell proliferation and colony formation in vitro. Our findings identify miR-483-3p as a potent regulator of DPC4/Smad4, which may provide a novel therapeutic strategy for the treatment of DPC4/Smad4-driven pancreatic cancer.
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112326     DOI: 10.1016/j.febslet.2010.11.039

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  55 in total

Review 1.  Smad-mediated regulation of microRNA biosynthesis.

Authors:  Matthew T Blahna; Akiko Hata
Journal:  FEBS Lett       Date:  2012-01-28       Impact factor: 4.124

2.  Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma.

Authors:  Yi Zhou; Liu Hong
Journal:  Genet Test Mol Biomarkers       Date:  2013-05-13

3.  Integrated microRNA and mRNA responses to acute human left ventricular ischemia.

Authors:  Louis A Saddic; Tzuu-Wang Chang; Martin I Sigurdsson; Mahyar Heydarpour; Benjamin A Raby; Stanton K Shernan; Sary F Aranki; Simon C Body; Jochen D Muehlschlegel
Journal:  Physiol Genomics       Date:  2015-07-14       Impact factor: 3.107

4.  CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest.

Authors:  T Bertero; C Gastaldi; I Bourget-Ponzio; B Mari; G Meneguzzi; P Barbry; G Ponzio; R Rezzonico
Journal:  Cell Death Differ       Date:  2013-02-22       Impact factor: 15.828

5.  miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.

Authors:  Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy
Journal:  Circ Res       Date:  2016-12-06       Impact factor: 17.367

6.  [Expressions of ΔNp63α, DPC4/Smad4 and P21 in cervical squamous cell carcinoma an their clinical significance].

Authors:  Wenqing Song; Tingting Huang; Lan Yu; Zenong Cheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

7.  A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants.

Authors:  Sha Tao; Zhong Wang; Junjie Feng; Fang-Chi Hsu; Guangfu Jin; Seong-Tae Kim; Zheng Zhang; Henrik Gronberg; Lilly S Zheng; William B Isaacs; Jianfeng Xu; Jielin Sun
Journal:  Carcinogenesis       Date:  2012-01-04       Impact factor: 4.944

Review 8.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 9.  miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Authors:  Anteneh A Tesfaye; Asfar S Azmi; Philip A Philip
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

10.  miR-483 targets SMAD4 to suppress chondrogenic differentiation of human mesenchymal stem cells.

Authors:  Britta A Anderson; Audrey McAlinden
Journal:  J Orthop Res       Date:  2017-03-13       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.